JP7836769B2 - ベンジルオキシリン酸エステル(ホスホン酸エステル)化合物 - Google Patents
ベンジルオキシリン酸エステル(ホスホン酸エステル)化合物Info
- Publication number
- JP7836769B2 JP7836769B2 JP2022562642A JP2022562642A JP7836769B2 JP 7836769 B2 JP7836769 B2 JP 7836769B2 JP 2022562642 A JP2022562642 A JP 2022562642A JP 2022562642 A JP2022562642 A JP 2022562642A JP 7836769 B2 JP7836769 B2 JP 7836769B2
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- group
- alkyl
- aryl
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4087—Esters with arylalkanols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
- C07F9/655381—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a seven-(or more) membered ring
- C07F9/65539—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a seven-(or more) membered ring condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
- C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025191949A JP2026032020A (ja) | 2020-04-21 | 2025-11-12 | ベンジルオキシリン酸エステル(ホスホン酸エステル)化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063013263P | 2020-04-21 | 2020-04-21 | |
| US63/013,263 | 2020-04-21 | ||
| PCT/US2021/027930 WO2021216431A1 (en) | 2020-04-21 | 2021-04-19 | Benzyloxy phosph(on)ate compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025191949A Division JP2026032020A (ja) | 2020-04-21 | 2025-11-12 | ベンジルオキシリン酸エステル(ホスホン酸エステル)化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023522866A JP2023522866A (ja) | 2023-06-01 |
| JP2023522866A5 JP2023522866A5 (cg-RX-API-DMAC7.html) | 2024-04-19 |
| JP7836769B2 true JP7836769B2 (ja) | 2026-03-27 |
Family
ID=78270233
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562642A Active JP7836769B2 (ja) | 2020-04-21 | 2021-04-19 | ベンジルオキシリン酸エステル(ホスホン酸エステル)化合物 |
| JP2025191949A Pending JP2026032020A (ja) | 2020-04-21 | 2025-11-12 | ベンジルオキシリン酸エステル(ホスホン酸エステル)化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025191949A Pending JP2026032020A (ja) | 2020-04-21 | 2025-11-12 | ベンジルオキシリン酸エステル(ホスホン酸エステル)化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12552820B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4139319A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7836769B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN115768778A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021216431A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019207626B2 (en) | 2018-01-10 | 2023-10-05 | Nucorion Pharmaceuticals, Inc. | Phosphor(n)amidatacetal and phosph(on)atalcetal compounds |
| WO2021011692A1 (en) | 2019-07-17 | 2021-01-21 | Nucorion Pharmaceuticals, Inc. | Cyclic deoxyribonucleotide compounds |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007094135A1 (ja) | 2006-02-15 | 2007-08-23 | Gifu University | オリゴヌクレオチド誘導体及びその利用 |
| WO2014043380A1 (en) | 2012-09-14 | 2014-03-20 | Ligand Pharmaceuticals Incorporated | Novel nucleotide prodrug compounds and use |
| WO2016138026A1 (en) | 2015-02-25 | 2016-09-01 | Ligand Pharmaceuticals, Inc. | Gemcitabine derivatives |
| US20190015432A1 (en) | 2017-07-13 | 2019-01-17 | Emory University | Lipid Disulfide Prodrugs and Uses Related Thereto |
| WO2019143860A1 (en) | 2018-01-19 | 2019-07-25 | Nucorion Pharmaceuticals, Inc. | 5-fluorouracil compounds |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6023120B2 (ja) | 1979-08-13 | 1985-06-05 | キッコーマン株式会社 | アデノシン−3′,5′−環状リン酸アルキルトリエステルの製造法 |
| DE3027279A1 (de) | 1980-07-18 | 1982-05-06 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Substituierte adenosin-3',5'-phosphorsaeurebenzyltriester, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| JPS61204193A (ja) | 1985-03-05 | 1986-09-10 | Takeda Chem Ind Ltd | シトシンヌクレオシド類の製造法 |
| CA1327358C (en) | 1987-11-17 | 1994-03-01 | Morio Fujiu | Fluoro cytidine derivatives |
| JPH0692987A (ja) | 1992-09-17 | 1994-04-05 | Tanabe Seiyaku Co Ltd | ウリジン誘導体およびその製法 |
| AU671491B2 (en) | 1992-12-18 | 1996-08-29 | F. Hoffmann-La Roche Ag | N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines |
| US5693521A (en) | 1993-04-09 | 1997-12-02 | The Regents Of The University Of California | Membrane-permeant second messengers |
| US5834436A (en) | 1993-04-09 | 1998-11-10 | The Regents Of The University Of California | Membrane-permeant second messengers |
| US5866548A (en) | 1993-04-09 | 1999-02-02 | The Regents Of The University Of California | Caged membrane-permeant inositol phosphates |
| US5476932A (en) | 1994-08-26 | 1995-12-19 | Hoffmann-La Roche Inc. | Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives |
| US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| HRP20030047B1 (hr) | 2000-07-21 | 2016-02-26 | Gilead Sciences, Inc. | Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava |
| CA2416527C (en) | 2000-08-10 | 2009-12-22 | Pharmacia Italia S.P.A. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| WO2002092006A2 (en) | 2001-05-16 | 2002-11-21 | Micrologix Biotech, Inc. | Nucleic acid-based compounds and methods of use thereof |
| KR20050035194A (ko) | 2002-06-28 | 2005-04-15 | 이데닉스 (케이만) 리미티드 | 플라비비리다에 감염 치료용 2'-c-메틸-3'-o-l-발린에스테르 리보푸라노실 사이티딘 |
| WO2005018330A1 (en) | 2003-08-18 | 2005-03-03 | Pharmasset, Inc. | Dosing regimen for flaviviridae therapy |
| ES2310860T3 (es) | 2004-12-17 | 2009-01-16 | Eli Lilly And Company | Profarmaco amida de gemcitabina, composiciones y uso del mismo. |
| WO2007027248A2 (en) | 2005-05-16 | 2007-03-08 | Valeant Research & Development | 3', 5' - cyclic nucleoside analogues for treatment of hcv |
| EP1915053A2 (en) | 2005-08-12 | 2008-04-30 | Merck & Co., Inc. | Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives |
| ES2436404T3 (es) | 2005-10-03 | 2013-12-30 | University Health Network | Inhibidores ODCasa para el tratamiento de malaria |
| JP2009531284A (ja) | 2006-02-06 | 2009-09-03 | ドクター レディズ ラボラトリーズ リミテッド | ゲムシタビンの調製 |
| FR2907786B1 (fr) | 2006-10-27 | 2009-09-18 | Univ Grenoble 1 | Thionucleosides et applications pharmaceutiques |
| US8338593B2 (en) | 2006-07-07 | 2012-12-25 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
| WO2008030373A2 (en) | 2006-09-01 | 2008-03-13 | University Of Georgia Research Foundation, Inc. | L- oddc prodrugs for cancer |
| WO2008083465A1 (en) | 2007-01-08 | 2008-07-17 | University Health Network | Pyrimidine derivatives as anticancer agents |
| WO2008144980A1 (fr) | 2007-05-25 | 2008-12-04 | Topharman Shanghai Co., Ltd. | Procédé de préparation et intermédiaires de la capécitabine |
| US8741858B2 (en) | 2007-09-21 | 2014-06-03 | Zhongxu Ren | Oligomer-nucleoside phosphate conjugates |
| WO2009061781A1 (en) | 2007-11-07 | 2009-05-14 | Schering Corporation | Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
| KR101013312B1 (ko) | 2007-11-19 | 2011-02-09 | 한미홀딩스 주식회사 | 카페시타빈의 제조방법 및 이에 사용되는 β-아노머가강화된 트리알킬카보네이트 화합물의 제조방법 |
| WO2009082846A1 (fr) | 2007-12-28 | 2009-07-09 | Topharman Shanghai Co., Ltd. | Dérivé hydroxyle de la capécitabine, ses procédés de préparation et ses utilisations pour préparer la capécitabine |
| EP2096114A1 (en) | 2008-02-27 | 2009-09-02 | Bayer CropScience AG | Insecticidal Derivates of Substituted Phosphorylated Phenylalkyl Iminooxazolines and Iminothiazolines |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| WO2010027326A1 (en) | 2008-09-03 | 2010-03-11 | Nanyang Technological University | Peptide nucleic acid monomers and oligomers |
| EP2350296A4 (en) | 2008-11-17 | 2013-04-03 | Enzon Pharmaceuticals Inc | BRANCHED CATIONIC LIPIDS FOR THE SYSTEM FOR INTRODUCING NUCLEIC ACIDS |
| EP2393472B1 (en) | 2008-12-05 | 2019-06-05 | NanoMed Holdings Pty Ltd | Amphiphile prodrugs |
| AR074897A1 (es) | 2008-12-23 | 2011-02-23 | Pharmasset Inc | Fosforamidatos de nucleosidos |
| CN101525361B (zh) | 2009-04-21 | 2010-11-17 | 济南圣鲁金药物技术开发有限公司 | 基于吉西他滨结构的前药及其合成方法及应用 |
| CN101875680B (zh) | 2009-04-28 | 2012-07-25 | 上海信旗医药科技有限公司 | 一种核苷类化合物及其制备方法和应用 |
| JO3027B1 (ar) | 2009-05-14 | 2016-09-05 | Janssen Products Lp | نيوكليوسيدات يوراسيل سبيرواوكسيتان |
| CN101921303A (zh) | 2009-06-09 | 2010-12-22 | 曾慧慧 | 苯并异硒唑酮二氟胞苷类化合物及其制备方法和其用途 |
| US8455451B2 (en) | 2009-09-21 | 2013-06-04 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| CN102939291B (zh) | 2010-04-14 | 2016-09-07 | 加利福尼亚大学董事会 | 用于病毒感染治疗的具有降低的毒性的膦酸酯 |
| CN102351931B (zh) | 2010-09-07 | 2014-01-22 | 河南省科学院高新技术研究中心 | 嘧啶核苷衍生物、合成方法及其在制备抗肿瘤、抗病毒药物中的应用 |
| US20120070411A1 (en) | 2010-09-22 | 2012-03-22 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| US20120142627A1 (en) | 2010-12-06 | 2012-06-07 | Emory University | Monophosphate prodrugs of dapd and analogs thereof |
| US8772474B2 (en) | 2010-12-22 | 2014-07-08 | Alios Biopharma, Inc. | Cyclic nucleotide analogs |
| CN102219817A (zh) | 2011-04-12 | 2011-10-19 | 连云港杰瑞药业有限公司 | 活性偶联剂用于氟化嘧啶化合物烷氧羰酰化的方法 |
| SI2827875T1 (sl) | 2012-03-21 | 2019-04-30 | Alios Biopharma, Inc. | Substituirani nukleozidi, nukleotidi in njihovi analogi |
| WO2013177195A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphate prodrugs for hcv infection |
| PT2861611T (pt) | 2012-05-25 | 2016-10-11 | Janssen Sciences Ireland Uc | Nucleósidos de espirooxetano de uracilo |
| CN107312039B (zh) | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
| US9872919B2 (en) | 2012-09-19 | 2018-01-23 | The Research Foundation For The State University Of New York | Prodrugs for selective anticancer therapy |
| ES2674980T3 (es) | 2012-10-08 | 2018-07-05 | Idenix Pharmaceuticals Llc | Análogos de 2'-cloro nucleósidos para infección por VHC |
| EP2909209B1 (en) | 2012-10-17 | 2022-08-03 | Merck Sharp & Dohme LLC | 2'-cyano substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases |
| US9227990B2 (en) | 2012-10-29 | 2016-01-05 | Cipla Limited | Antiviral phosphonate analogues and process for preparation thereof |
| US9447137B2 (en) | 2012-11-07 | 2016-09-20 | Nucorion Pharmaceuticals, Inc. | Substituted gemcitabine aryl amide analogs |
| JP2016501200A (ja) | 2012-11-19 | 2016-01-18 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | ウイルス性疾患を処置するための2−アルキニル置換ヌクレオシド誘導体 |
| US9243022B2 (en) | 2012-12-21 | 2016-01-26 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| WO2014124430A1 (en) | 2013-02-11 | 2014-08-14 | Emory University | Nucleotide and nucleoside therapeutic compositions and uses related thereto |
| WO2014145207A1 (en) | 2013-03-15 | 2014-09-18 | Ohio State Innovation Foundation | Substituted gemcitabine bicyclic amide analogs and treatment methods using same |
| WO2014204831A1 (en) | 2013-06-18 | 2014-12-24 | Merck Sharp & Dohme Corp. | Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| EP3074399A1 (en) | 2013-11-27 | 2016-10-05 | Idenix Pharmaceuticals LLC | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
| JP2017504572A (ja) | 2013-11-27 | 2017-02-09 | アイデニクス・ファーマシューティカルズ・エルエルシー | 肝臓癌治療のためのヌクレオチド類 |
| WO2015134334A1 (en) | 2014-03-03 | 2015-09-11 | Suo Zucai | Gemcitabine analogs |
| EP3131914B1 (en) | 2014-04-16 | 2023-05-10 | Idenix Pharmaceuticals LLC | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
| AU2015265607A1 (en) | 2014-05-28 | 2016-11-17 | Idenix Pharmaceuticals Llc | Nucleoside derivatives for the treatment of cancer |
| WO2017019581A1 (en) | 2015-07-29 | 2017-02-02 | Merck Sharp & Dohme Corp. | Process for making phosphorus-containing nucleoside prodrug compounds |
| JP6743135B2 (ja) | 2015-09-02 | 2020-08-19 | アッヴィ・インコーポレイテッド | 抗ウィルス性テトラヒドロフラン誘導体 |
| CN106554382B (zh) | 2015-09-29 | 2019-12-03 | 四川科伦博泰生物医药股份有限公司 | 核苷磷酰胺类化合物及其制备方法和药物中的应用 |
| US20200179428A1 (en) | 2016-06-20 | 2020-06-11 | Merck Sharp & Dohme Corp. | Cyclic phosphate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| EP3471737B1 (en) | 2016-06-20 | 2025-06-04 | Merck Sharp & Dohme LLC | Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases |
| US11364257B2 (en) | 2016-06-24 | 2022-06-21 | Emory University | Phosphoramidates for the treatment of hepatitis B virus |
| CN106317116A (zh) | 2016-08-19 | 2017-01-11 | 张红利 | 磷酰胺核苷类化合物及其药学上可接受的盐与应用、药物组合物 |
| US20190365788A1 (en) | 2016-11-21 | 2019-12-05 | Idenix Pharmaceuticals Llc | Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases |
| US10899786B2 (en) | 2016-12-23 | 2021-01-26 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Nucleoside phosphate compound and preparation method and use thereof |
| CN111491634A (zh) | 2017-07-31 | 2020-08-04 | 詹纽瑞治疗公司 | 有机磷酸酯衍生物 |
| US10435429B2 (en) | 2017-10-03 | 2019-10-08 | Nucorion Pharmaceuticals, Inc. | 5-fluorouridine monophosphate cyclic triester compounds |
| CN109956986B (zh) | 2017-12-22 | 2021-04-27 | 浙江柏拉阿图医药科技有限公司 | 肝递送吉西他滨前体药物核苷环磷酸酯化合物及应用 |
| AU2019207626B2 (en) | 2018-01-10 | 2023-10-05 | Nucorion Pharmaceuticals, Inc. | Phosphor(n)amidatacetal and phosph(on)atalcetal compounds |
| US11427550B2 (en) * | 2018-01-19 | 2022-08-30 | Nucorion Pharmaceuticals, Inc. | 5-fluorouracil compounds |
| AU2019227986A1 (en) | 2018-03-02 | 2020-10-08 | January Therapeutics, Inc. | Nanoparticle compositions |
| WO2020154917A1 (en) | 2019-01-29 | 2020-08-06 | Minghui Pharmaceutical (Shanghai) Limited | Phosphate and phosphonate based compounds of 6-thio-2'-deoxyguanosine as anti-cancer agents |
| MX428883B (es) | 2019-04-22 | 2025-11-13 | Ligand Pharm Inc | Compuestos ciclicos de fosfato |
| WO2020227132A1 (en) | 2019-05-03 | 2020-11-12 | Terns, Inc. | Compounds for treating cancer |
| WO2021011692A1 (en) | 2019-07-17 | 2021-01-21 | Nucorion Pharmaceuticals, Inc. | Cyclic deoxyribonucleotide compounds |
| EP4143199B1 (en) * | 2020-04-21 | 2025-11-19 | Ligand Pharmaceuticals, Inc. | Nucleotide prodrug compounds |
| WO2022086858A1 (en) | 2020-10-19 | 2022-04-28 | Aptinyx Inc. | Methods of treating post-traumatic stress disorder and related conditions |
| JP7699205B2 (ja) | 2020-10-21 | 2025-06-26 | リガンド・ファーマシューティカルズ・インコーポレイテッド | 抗ウイルスプロドラッグ化合物 |
| US20240294565A1 (en) | 2021-05-17 | 2024-09-05 | Ligand Pharmaceuticals Incorporated | Unnatural configuration nucleotide prodrug compounds |
-
2021
- 2021-04-19 WO PCT/US2021/027930 patent/WO2021216431A1/en not_active Ceased
- 2021-04-19 CN CN202180036572.3A patent/CN115768778A/zh active Pending
- 2021-04-19 JP JP2022562642A patent/JP7836769B2/ja active Active
- 2021-04-19 EP EP21793248.2A patent/EP4139319A4/en active Pending
- 2021-04-19 US US17/996,613 patent/US12552820B2/en active Active
-
2025
- 2025-11-12 JP JP2025191949A patent/JP2026032020A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007094135A1 (ja) | 2006-02-15 | 2007-08-23 | Gifu University | オリゴヌクレオチド誘導体及びその利用 |
| WO2014043380A1 (en) | 2012-09-14 | 2014-03-20 | Ligand Pharmaceuticals Incorporated | Novel nucleotide prodrug compounds and use |
| WO2016138026A1 (en) | 2015-02-25 | 2016-09-01 | Ligand Pharmaceuticals, Inc. | Gemcitabine derivatives |
| US20190015432A1 (en) | 2017-07-13 | 2019-01-17 | Emory University | Lipid Disulfide Prodrugs and Uses Related Thereto |
| WO2019143860A1 (en) | 2018-01-19 | 2019-07-25 | Nucorion Pharmaceuticals, Inc. | 5-fluorouracil compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230159574A1 (en) | 2023-05-25 |
| US12552820B2 (en) | 2026-02-17 |
| JP2026032020A (ja) | 2026-02-25 |
| JP2023522866A (ja) | 2023-06-01 |
| WO2021216431A1 (en) | 2021-10-28 |
| CN115768778A (zh) | 2023-03-07 |
| EP4139319A1 (en) | 2023-03-01 |
| EP4139319A4 (en) | 2024-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI838355B (zh) | 5-氟尿嘧啶化合物 | |
| JP7661235B2 (ja) | 環状リン酸エステル化合物 | |
| TWI870583B (zh) | 核苷酸前藥化合物 | |
| JP7181938B2 (ja) | ホスホロ(ン)アミダートアセタールおよびホスファ(ホナ)ートアルセタール化合物 | |
| US10435429B2 (en) | 5-fluorouridine monophosphate cyclic triester compounds | |
| JP7699205B2 (ja) | 抗ウイルスプロドラッグ化合物 | |
| JP2026032020A (ja) | ベンジルオキシリン酸エステル(ホスホン酸エステル)化合物 | |
| JP7625542B2 (ja) | 環状デオキシリボヌクレオチド化合物 | |
| RU2836016C2 (ru) | Циклические дезоксирибонуклеотидные соединения | |
| HK40105750A (en) | Phosphor(n)amidatacetal and phosph(on)atalcetal compounds | |
| HK40108726A (en) | Phosphor(n)amidatacetal and phosph(on)atalcetal compounds | |
| HK40063264A (en) | Cyclic deoxyribonucleotide compounds | |
| HK40063264B (en) | Cyclic deoxyribonucleotide compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20230726 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240329 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240329 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250220 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250305 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250530 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20250717 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251112 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251117 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260303 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260316 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7836769 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |